- Ongoing, recruitingTherapeutic exploratory (Phase II)
HepaStem Long-Term Safety Registry – Registry for Patients who have been administered HepaStem
This study is a long-term check-up for people who have already had a treatment called HepaStem for certain liver or genetic conditions. Researchers want to see how everyone who received HepaStem is doing over time, focusing on any serious health changes.
For: Crigler-Najjar (CN) and Fibroinflammatory liver diseases.Spain · Belgium · France - Ongoing, recruitingTherapeutic exploratory (Phase II)
Randomized, placebo-controlled, double blind, multi-centre Phase IIb stuDy to evaluate the efficacy and safety of HepaStem in patients with Acute on Chronic Liver Failure (ACLF) – DHELIVER
This study, called DHELIVER, is testing a new treatment, HepaStem, for people with severe liver failure called ACLF. It aims to see if HepaStem can help people live longer and improve their liver health.
For: Cirrhotic patients who are hospitalized for Acute on chronic liver failure (ACLF)Denmark · Poland · Bulgaria